• / Free eNewsletters & Magazine
  • / My Account
Home>Novo's Scale Advantages and Drug Lineup Broaden Its Wide Moat

Novo's Scale Advantages and Drug Lineup Broaden Its Wide Moat

Morningstar Articles

Wed, 3 Jul 2013

Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.

Related Videos

  1. What We Can Expect From Second-Quarter Earnings

    Morningstar's Heather Brilliant says investors could see a lot of market volatility this upcoming earnings season, but that could make for tremendous buying opportunities of quality names.

  2. Why Moats Matter

    An economic moat provides a gauge of a company's competitive advantages and overall strength, and it is a highly valuable tool for investors of all levels.

  3. The Friday Five

    Five stats from the market and the stories behind them. This week: three wide - moat names worth a look, an 89-day deal in Washington, and more.

  4. Ready Your Portfolio for Retirement

    Morningstar's Christine Benz demonstrates how to make a bucket portfolio best work for you, touching on allocation, RMDs, other income sources, and more.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.